author-photo

Dunnya De-Silva

University College London Hospitals NHS Foundation Trust

10

Papers

6

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
The promoting individualised self-management and survivorship (PrISMS) clinic - A multidisciplinary remote monitoring clinic for a patient-centred approach in multiple myeloma

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Real World Use of Ixazomib With Lenalidomide and Dexamethasone for Patients With Relapsed Multiple Myeloma

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
MARROW INFILTRATING T-REGULATORY CELLS ASSOCIATE WITH PD-1 EXPRESSING CD4 EFFECTOR CELLS AND INFERIOR OUTCOMES IN PATIENTS UNDERGOING NOVEL-AGENT REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): PF563

2019
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving ≥VGPR following PAD induction in the Phase 2 PADIMAC study

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

2017 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Clinical Benefit of Depth of Response for Relapsed/Refractory Multiple Myeloma Patients Treated on Clinical Trials: Retrospective Analysis from Two Tertiary Centres

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)